Enroll In Study

About Us
Capabilities
Why Orphanos?
Meet Our Team
Careers

Free White Paper. PDF Download Free White Paper: 2016 Overview of Novel Orphan Drugs

Latest Blogs

NORD Issues Statement as House Committees Review the American Health Care Act

20th March 2017 | Orphanos

Washington, D.C., March 8, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in advance... Read more

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis

21st February 2017 | Orphanos

CORAL GABLES, Fla., Sept. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today... Read more

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

16th February 2017 | Orphanos

– Actimab-A has received Orphan Drug Designation in the U.S. – Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity NEW... Read more

Request for Proposal

Should be Empty:

Contact Us

Location

116 Villard St. W,
Dickinson, ND 58601

Telephone: 701 - 483 - 3599

/

Fax: 701 - 483 - 1556

Mankato Web Design